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The chemopreventive NO-donating NSAIDs (NO-NSAIDs; NSAIDs with an NO-releasing moiety) modulate PPARδ and oﬀer
the opportunity to revisit the controversial role of PPARδ in carcinogenesis (several papers report that PPARδ either promotes or
inhibits cancer). This review summarizes the pharmacology of NO-NSAIDs, PPARδ cancer biology, and the relationship between
the two. In particular, a study of the chemopreventive eﬀect of two isomers of NO-aspirin on intestinal neoplasia in Min mice
showed that, compared to wild-type controls, PPARδ is overexpressed in the intestinal mucosa of Min mice; PPARδ responds to
m-a n dp-NO-ASA proportionally to their antitumor eﬀect (p- >m -). This eﬀect is accompanied by the induction of epithelial
cell death, which correlates with the antineoplastic eﬀect of NO-aspirin; and NO-aspirin’s eﬀect on PPARδ is speciﬁc (no changes
in PPARα or PPARγ). Although these data support the notion that PPARδ promotes intestinal carcinogenesis and its inhibition
could be therapeutically useful, more work is needed before a ﬁrm conclusion is reached.
Copyright © 2008 Gerardo G. Mackenzie et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Cancer represents a major health challenge of our time. In
the last decade, biomedical science has pursued with unusual
vigor the molecular understanding of cancer. Cell signal-
ing cascades have, in particular, been examined or even
recognized in the context of cancer research. The implicit
assumption (as well as the expectation) has been that under-
standing the mechanisms of carcinogenesis will facilitate the
development of rational, mechanism-driven interventions
for either the treatment or even better the prevention of
cancer. The ultimate “deliverable” of such systematic eﬀorts
will be successful cancer therapeutic or preventive agents.
As is, however, sometimes the case in science, mechanis-
tic progress can also be made while trying to understand the
mode of action of agents already developed. Such appears to
be the case with the opportunity that presented itself while
we were exploring the mode of action of a novel chemo-
preventive agent, nitric oxide-donating aspirin (NO-ASA),
and its relationship to peroxisome proliferator-activated re-
ceptor δ (PPARδ). Here, we discuss our ﬁndings, and to
provide an appropriate perspective, we summarize relevant
aspects of the pharmacology of nitric oxide-donating non-
steroidal anti-inﬂammatory drugs (NO-NSAIDs), PPARδ
cancer biology, and the relationship between the two.
2. NO-NSAIDs AND CANCER
NO-ASA, initially intended for rheumatologic and cardio-
vascular applications [1, 2], is a member of a large family
of pharmacologically active compounds known as NO-
donating NSAIDs (NO-NSAIDs). NO-NSAIDs consist of a
conventional NSAID to which the NO-releasing moiety–
ONO2 has been attached via a chemical linker [3, Figure 1].
In the case of NO-ASA, the spacer can vary in its chemical
structure, generating a great number of derivatives. There
are three positional isomers of the NO-ASA molecule (ortho,
meta,a n dpara), generated by varying the position of the –
CH2ONO2 group with respect to the ester bond linking the
two benzenes [4]. NO-ASA is the best studied NO-NSAID to
date.2 PPAR Research
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Figure 1: Eﬀect of NO-ASA on PPARδ and other signaling pathways. NO-ASA consists of a traditional ASA molecule (shaded), the spacer,
and –ONO2, which releases NO, with the molecule being considered responsible for much of its pharmacological properties. There are three
positional isomers of NO-ASA (ortho, meta,a n dpara), depending on the position of –ONO2 in the benzene ring with respect to the ester
bond linking the ASA and spacer moieties. NO-ASA aﬀects several cell signaling pathways, all relevant to carcinogenesis. The modulation of
these often cross-talking pathways culminates in a net inhibitory eﬀect on cell growth, one of the crucial determinants of the fate of a tumor.
It is likely that such mechanistic pleiotropism by NO-ASA is central to its eﬃcacy against cancer.
The impetus for the development of NO-NSAIDs for
cancer prevention has been provided by extensive epidemi-
ological data and interventional studies which over ﬁfteen
years have established conclusively conventional NSAIDs as
chemopreventive agents against colon and other cancers
[5, 6]. The limited eﬃcacy (less than 50%) and side eﬀects
that accompany NSAIDs have prompted the search for
better performing agents. NO-NSAIDs, especially NO-ASA,
promise to be such an alternative, and their anticancer
properties are now under intense study by our group and
others. Even though signiﬁcant progress has been made, the
mechanism by which NO-ASA exerts its chemopreventive
eﬀect against colon cancer is still not completely understood
[2]. Our data indicate that NO-ASA could exert its colon
chemopreventive eﬀect, at least in part, by modulating
PPARδ function [7].
Extensive preclinical results have established that NO-
ASA, which is now FDA approved for clinical trials, displays
properties consistent with a chemopreventive eﬀect [8].
These ﬁndings can be grouped into those documenting a
favorablein vitro cytokinetic eﬀect and those demonstrating
chemopreventive eﬃcacy in animal models of cancer. Com-
pared to their corresponding parent compounds, several
NO-NSAIDs (including NO-ASA, NO-sulindac and NO-
ibuprofen, NO-salicylic acid, NO-indomethacin, and NO-
ﬂurbiprofen) have greater potency in inhibiting the growth
of cancer cell lines, for example, colon, prostate, lung,
pancreas, tonsil, breast cancer, and leukemia [9–12]. For
example, in the case of colon cancer cell lines, the IC50
values of NO-NSAIDs were enhanced between 1.7- and
1083-fold. The growth-inhibitory eﬀect of NO-NSAIDs is
due to a profound cytokinetic eﬀect, consisting of reduced
cell proliferation, enhanced cell death, and inhibition of cell-
cycle-phase transitions. Beyond classical apoptosis, NO-ASA
induced another form of cell death, termed as atypical cell
death [4]. Likely, a form of cell necrosis, atypical cell death,
wasinitiallydescribedinvitro,butmayactuallyoccurinvivo
[7].
The in vivo studies used orthotopic animal models of
cancer as well as xenotransplants of human cancer cell lines
in appropriate murine hosts. For colon cancer, the results
from the various models are congruent and demonstrate a
clear-cut chemopreventive eﬀect. In Min mice, 3weeks of
treatment with NO-ASA decreased the number of tumors
by 55% [13]. In F344 rats treated with the carcinogen
azoxymethane, NO-indomethacin and meta NO-ASA sig-
niﬁcantly suppressed both tumor incidence and multiplicity
(NO-indomethacin was more eﬀective than NO-ASA). Of
the two NO-ASA isomers, the para was more eﬃcacious
than the meta in Min mice [4]. When combined with 5-
ﬂuorouracil or oxaliplatin, para NO-ASA showed additive
eﬀects [14]. Sequential NO-ASA and oxaliplatin treatment
reduced tumor growth more eﬀectively than single-drug
treatments, perhaps by sensitizing colon cancer cells to
the eﬀect of antitumor drugs. Studies using a hamster
modelofpancreaticcancergeneratedimpressiveresults[15].
Compared with the control group, NO-ASA reduced the
incidence and multiplicity of pancreatic cancer by 88.9%
and 94%, respectively, whereas conventional ASA had no
signiﬁcant eﬀect.
An exciting aspect of NO-ASA is its extraordinarily
enhanced potency. We and others have attempted to under-
stand this through studies assessing their eﬀects on poten-
tially informative pathways (summarized in [8]). It appears
that NO-ASA has a pleiotropic eﬀect involving several
pathways, as depicted in Figure 1.P P A R δ is a signiﬁcantGerardo G. Mackenzie et al. 3
component of this array of signaling molecules [7, 16–19].
Below, after an overview of the role of PPARδ in cancer, we
discuss the relationship between NO-ASA and PPARδ.
3. PPARδ AND CANCER
PPARs, having their ﬁrst member cloned in 1990 [20], are
ligand-activatedtranscriptionfactorsbelongingtothesuper-
family of nuclear receptors. They facilitate the response of
cells to extracellular stimuli by transcriptionally regulating
gene expression [21, 22]. Three distinct PPAR subclasses
have been identiﬁed: PPARα,P P A R δ (also referred to as
PPARβ/δ), and PPARγ. These isoforms are encoded by
separate genes and diﬀer in their tissue distribution and
function.PPARδ isthemoreubiquitouslyexpressedisoform.
Each of the PPAR isoforms heterodimerizes with the 9-
cis-retinoic receptor, their obligate partner. PPARs regulate
diverse physiological processes ranging from lipogenesis to
inﬂammation, and have been implicated in several disorders
including the metabolic syndrome, diabetes, and atheroscle-
rosis, as well as cancer. More recently, PPARγ was shown to
play a signiﬁcant role in cell growth, inﬂammation, apopto-
sis, and angiogenesis [23–27].
The study of PPARδ lags behind our fairly advanced
understanding of PPARα and PPARγ; the development of
high-aﬃnity PPARδ agonists has recently expedited progress
[28, 29]. PGI2 and cPGI are naturally occurring PPARδ ago-
nists [30]. PPARδ is involved in a wide range of phenomena
aﬀecting several functions, and some of them are critical to
thelifeofanorganism.PPARδ stimulatesfattyacidoxidation
in heart and skeletal muscle [31, 32] ,a n dp l a y sar o l ei nc e l l
diﬀerentiation [33–35], placental development [36], cancer,
wound repair [37], and atherosclerosis [38–41]. PPARδ-null
mouse models revealed that PPARδ deﬁciency is associated
with multiple developmental and metabolic abnormalities,
including frequent embryonic lethality [36].
4. THE PROS AND CONS FOR A ROLE OF
PPARδ IN CANCER
There have been both signiﬁcant work on and signiﬁcant
excitementaboutapotentialroleofPPARδ incancer.Aswith
any evolving ﬁeld, some controversy is almost inevitable.
This controversy arises mainly from the varying results from
animal studies (summarized in [42]). Available data can
be divided into two: those which support the notion that
PPARδ plays a crucial role in carcinogenesis, and those
which indicate that PPARδ is devoid of any such role. Below,
we present the main points supporting each one of these
antithetic conclusions (Table 1).
4.1. Pros
PPARδ was ascribed as an oncogenic function after being
identiﬁed as a direct transcriptional target of β-catenin,
and as a repression target of the NSAID sulindac, a potent
suppressor of colorectal tumors [44]. A close association
between PPARδ and colon carcinogenesis was suggested by
immunohistochemical analyses showing that the expression
of PPARδ increases progressively as the colonic epithelium
advances from normal to malignant [45].
A series of observations in Min mice support a procar-
cinogenic role of PPARδ. When Min mice were treated with
azoxymethane, PPARδ levels were increased in ﬂat dysplastic
aberrant crypt foci [65], although the same authors indicate
that PPARδ expression in adenomas from Min mice does
not diﬀer compared to normal epithelium [65]. Deletion of
PPARδ decreased intestinal adenoma growth and inhibited
the tumor-promoting eﬀects of a PPARδ agonist [51].
Interestingly, the same group also showed that prostaglandin
E2 (PGE2), the predominant prostanoid found in most col-
orectal cancers, indirectly transactivates PPARδ promoting
cell survival and intestinal adenoma formation [53]. PGE2
treatment did not increase intestinal adenoma burden in
Min mice lacking PPARδ, concluding that PPARδ is a focal
point of cross-talk between the prostaglandin and Wnt
signaling pathways, which results in a shift from cell death
to cell survival, leading to increased tumor growth [53].
Treatment of Min mice with a synthetic agonist of PPARδ
increased signiﬁcantly the number and size of intestinal
polyps. The most prominent eﬀect was on polyp size;
the PPARδ activator increased the number of polyps by
>2mm ﬁve-fold [47]. The same group also showed that
compared with control ApcMin/+ mice (Ppard
+/+/ApcMin/+),
small intestinal polyps in PPARδ-deﬁcient ApcMin/+ mice
(Ppard
−/−/ApcMin/+) were reduced three-fold; the number
of large polyps (>1mm) was reduced about ten-fold.
Heterozygous deletion of PPARδ (Ppard
+/−/ApcMin/+) did
not signiﬁcantly reduce the total number of small and
large intestinal polyps in malemice, but this disruption
signiﬁcantly diminished the number of small intestinal
polyps that were >1mm[51].
In cultured colon cancer cells, PPARδ inhibited diﬀer-
entiation, conferred apoptotic resistance, and promoted cell
migration [43], whereas prostacyclin, a metabolic product
of COX-2 which modulates intestinal tumorigenesis [66],
increased PPARδ activity [43]. PPARδ expression was ele-
vated in colon cancer cells and was repressed by apc via
the β-catenin/TCF-4 response elements in its promoter [44].
Genetic disruption of Ppard decreased the tumorigenicity
of human coloncancer cells [46]. HCT116 Ppard
−/− cells,
inoculatedasxenograftsontonudemice,exhibiteddecreased
ability to form tumors compared to Ppard
+/− and wild-type
controls [46]. Dietary ﬁsh oil/pectin protected rats against
radiation-enhanced colon cancer by upregulating apoptosis
in colonic mucosa, in part, by suppressing PPARδ [48].
Data from noncolonic cell lines and tissues also support
ar o l ef o rP P A R δ in cancer. Activation of PPARδ results
in increased growth in sex hormone-responsive breast
(T47D, MCF7) and prostate (LNCaP, PNT1A) cell lines
[52]. Epithelial ovarian cancer cells express high levels of
PPARδ, and inhibition of PPARδ reduced tumor growth
[50]. In epithelial ovarian cancer cells, aspirin suppressed
PPARδ function and cell growth by inhibiting ERK1/2
[50]. Activation of PPARδ by its pharmacologic ligand
GW501516 enhanced the growth of human hepatoma cell
lines, whereas PPARδ knockdown by siRNA prevented cell4 PPAR Research
Table 1: The pros and cons for a role of PPARδ in cancer.
Evidence Reference
Pros
PPARδ expression is enhanced in colon cancer cells [43]
PPARδ expression is repressed by the APC gene [44]
PPARδ expression increases as tumor progresses [45]
PPARδ genetic disruption decreases tumorigenicity of colorectal cancer cells [46]
PPARδ activation accelerates intestinal adenoma growth in Min mice [47]
Ppard−/− HCT116 cells exhibit decreased ability to form xenograft tumors [46]
Dietary ﬁsh oil/pectin protects against radiation-enhanced colon cancer by upregulating apoptosis, in part, [48]
through PPARδ suppression
PPARδ expression levels are correlated with advanced pathological tumor stage in tumor patients [49]
PPARδ-targeted removal of a hub node of the angiogenic network markedly impairs angiogenesis
[49]
and tumor growth in mice
Inhibition of PPARδ function reduces growth of epithelial ovarian cancer [50]
Activation of PPARδ upregulates VEGF in colon cancer cells [51]
PPARδ activation stimulates the proliferation of human breast and prostate cancer cell lines [52]
PGE2 indirectly transactivates PPARδ promoting cell survival and intestinal adenoma formation [53]
Cons
PPARδ-null Min mice exhibit increased predisposition to intestinal tumorigenesis [54]
PPARδ-deﬁcient mice show higher polyp formation [55]
PPARδ agonists do not increase cell growth in human cancer cell lines [56]
PPARδ is dispensable for polyp formation in the intestine and colon of Min mice [36]
RNA interference against Ppard promotes proliferation of HCT116 cells [57]
Lung tumorigenesis is attenuated in mice with disrupted Ppard [58]
PPARδ does not modify impaired mismatch repair-induced neoplasia [59]
PPARδ promotes diﬀerentiation, inhibiting cell proliferation in keratinocytes [60]
PPARδ ligands inhibit TNFα-induced expression of the vascular cell adhesion molecule-1 and
[61]
E-selectin in HUVEC, preventing inﬂammation
Inhibition of colon carcinogenesis by a PPARδ a g o n i s ti na na z o x y m e t h a n em o u s em o d e l [62]
PPARδ activators inhibit TNFα-induced endothelial inﬂammation, in part by interfering with
[63]
the NF-κB signaling pathway
PPARδ activation by a PPARδ agonist produces no change in colon cancer cell growth [52]
PPARδ activation by GW0742 inhibits colon polyp multiplicity in Ppard
+/+ mice,
[64]
but not in Ppard
−/− mice
growth [67]. In murine knockout experiments, targeted
removal of a hub node (PPARδ) of the angiogenic network
markedly impaired angiogenesis and tumor growth [49].
In human cholangiocarcinoma, a positive feedback loop
between PPARδ and PGE2 was recognized; this interaction
plays an important role in cell growth [68]. In patients
with pancreatic cancer, PPARδ levels were correlated with
advanced pathological tumor stage, increasing the risk of
tumor recurrence and distant metastases [49].
4.2. Cons
The strongest evidence that PPARδ plays no appreciable role
in carcinogenesis comes from a series of animal studies, cell
culture data, and from studies evaluating the role of PPARδ
in inﬂammation, the latter being considered as a contributor
to carcinogenesis.
Barak et al. evaluated the hypothesis that if PPARδ
is a critical transducer of the tumorigenic signal, then its
loss should substantially reduce, ifnot eliminate, intestinal
polyps in Min mice [36]. Min mice that were Ppard-null
harbored intestinal and colonic polyps. Histologically, all
of the 12 intestinal polyps from Ppard
+/+ mice and the 9
from Ppard
−/− mice were low-grade tubular adenomas. The
number of intestinal polyps was not signiﬁcantly diﬀerent
between Ppard
+/+, Ppard
+/−,a n dPpard
−/− Min mice.
Loss of PPARδ did not signiﬁcantly change the median
size of intestinal polyps, although polyps > 1mm were
d e c r e a s e du p o nP P A R δ dosage reduction, which was furtherGerardo G. Mackenzie et al. 5
pronounced for polyps > 2mm. The number of polyps
< 1mm was essentially identical in all PPARδ genotype
groups. Their conclusion was that PPARδ is qualitatively
dispensable forthetumorigenic process,althoughtheycould
not rule out the possibility that it inﬂuences the pace of
polyp growth. In agreement with these ﬁndings, Marin
et al. showed that PPARδ activation by GW0742 inhibits
colon polyp multiplicity in Ppard
+/+ but not in Ppard
−/−
mice, suggesting that ligand activation of PPARδ attenuates
azoxymethane-induced colon carcinogenesis [64].
The most striking resultis provided by a study demon-
strating that in Min mice diﬀering in their Ppard geno-
type (Ppard
−/−, which did not express PPARδ protein;
Ppard
+/−;a n dPpard
+/+), the incidence of polyp formation
was not signiﬁcantly diﬀerent between groups [54]. In
fact, Ppard
−/− Min mice had about 3–6 times as many
colon polyps as those of Ppard
+/+ or Ppard
+/− mice. No
signiﬁcant diﬀerences in polyp size were found between any
of the genotypes. Congruent results were obtained when
they examined colon carcinogenesis with a more colon-
speciﬁc, azoxymethane-induced model. The data from these
two diﬀerent colorectal cancer models suggest that PPARδ
attenuates colon carcinogenesis.
Finally, Reed et al. reported that PPARδ-null Min mice
exhibited increased predisposition to intestinal tumorigen-
esis [55]. Another report from the same group, evaluating
the incidence and severity of intestinal neoplasia in mice
deﬁcient in both PPARδ and the mismatch repair gene Mlh1,
showed that deﬁciency of PPARδ in mice with compromised
mismatch DNA repair failed to aﬀect intestinal neoplasia
[59], with the implication being that PPARδ is not required
for intestinal adenoma formation.
Similar results have been obtained for noncolonic tu-
mors. For example, mice lacking one or both alleles of
Ppard h a de n h a n c e dg r o w t ho fl u n gt u m o r s[ 58]. In another
example, the onset of tumor formation, tumor size, and
tumor multiplicity of the skin was signiﬁcantly enhanced in
PPARδ-null mice compared with wild-type mice [69].
There are also data from cell culture models contradict-
ing the notion that PPARδ plays a role in carcinogenesis.
For example, in several human cancer cell lines, two PPARδ
ligands failed to increase cell growth, Akt phosphorylation,
or the expression of VEGF or COX-2 [56]. PPARδ activation
by a PPARδ agonist does not induce cell growth in HT29,
SW480, and HCA-7 colon cancer cells [64]. Furthermore,
Raf oncogenes can contribute to tumorigenesis by augment-
ingthesecretionoftumorgrowthpromotingprostaglandins,
such as PGI2. However, using several cell lines, Fauti et
al. showed that the increase in PGI2 synthesis did not
induce the transcriptional activity of PPARδ, suggesting
that the oncogenic eﬀect of PGE2 does not involve PPARδ
[70]. Another PPARδ function is the modulation of cell
cycle. Knockdown of the PPARδ gene by siRNA promoted
proliferation of HCT116 cells, suggesting that PPARδ may,
in fact, inhibit their proliferation by arresting them in the G1
phase of the cell cycle [57].
The chemopreventive action of PPARδ is also suggested
by studies showing that in many cell types PPARδ promotes
diﬀerentiation and inhibits proliferation [33, 60, 69, 71]. For
example, Hollingshead et al. examined in azoxymethane-
treated PPARδ-null mice whether PPARδ activation and
COX2inhibitionattenuatecoloncancerindependently.Inhi-
bition of COX2 by nimesulide attenuated colon cancer, and
activation of PPARδ by GW0742 had inhibitory eﬀects. The
eﬀects of these compounds occurred through independent
mechanisms as increased levels of diﬀerentiation markers
resulting from ligand activation of PPARδ were not found
with COX-2 inhibition, and reduced PGE2 levels resulting
from COX-2 inhibition were not observed in response to
ligand activation of PPARδ [62]. In another study by the
same group, wild-type (Ppard
+/+)a n dPpard
−/− mice
were treated with azoxymethane, together with GW0742,
as p e c i ﬁ cP P A R δ ligand, to test if Ppard
−/− mice exhibit
increased colon polyp multiplicity [64]. Ligand activation of
PPARδ in Ppard
+/+ mice increased the expression of mRNA
encoding the adipocyte diﬀerentiation-related protein, fatty
acid-binding protein, and cathepsin E, all being indicative
of colonocyte diﬀerentiation [64]. Thus, the induction of
diﬀerentiationandtheinhibitionofproliferationinresponse
to PPARδ activation support the hypothesis that PPARδ
attenuates colon carcinogenesis [62].
Another contrarian point of view concerns the role of
PPARδ in inﬂammation, with studies suggesting that activa-
tion of PPARδ has anti-inﬂammatory eﬀects. In hepatocytes,
the PPARδ agonist suppressed IL-6-mediated acute phase
reaction, prompting the speculation that PPARδ agonists
may be used to suppress systemic inﬂammatory reactions in
which IL-6 plays a central role [72]. Two synthetic PPARδ
ligands inhibited TNFα-induced expression of the vascular
cell adhesion molecule-1 and E-selectin in human umbilical
vein endothelial cells, suggesting that PPARδ activation has a
potent anti-inﬂammatory eﬀect [61].
Relevant to cancer is the presumed role of PPARδ in
inﬂammation and NF-κB regulation [63, 73, 74]. Such a role
is exempliﬁed by studies on the skin, where activation of
PPARδ by IFN-γ and TNFα accelerated keratinocyte diﬀer-
entiation[75].StudieswithPPARδ agonistshaveshownanti-
inﬂammatory properties of PPARδ attributed to inhibition
of NF-κB DNA-binding activity [74, 76]. Inﬂammation
induced by TPA (O-tetradecanoylphorbol-13-acetate) in the
skin was lower in wild-type mice fed sulindac than in sim-
ilarly treated PPARδ-null mice [77]. In human endothelial
cells, PPARδ activators inhibited TNFα-induced endothelial
inﬂammation (VCAM-1 expression, monocyte adhesion,
and MCP-1 secretion), in part by interfering with the
NF-κB signaling pathway [63]. Lipopolysaccharide-induced
TNFα production in cultured cardiomyocytes through NF-
κB activation was inhibited by overexpression of PPARδ or
the PPARδ synthetic ligand GW0742 [73].
The foregoing arguments and counterarguments make
it clear that this controversy remains unresolved. This is
the reason why we attempted to obtain an insight into the
role of PPARδ in carcinogenesis by exploiting the unique
opportunity oﬀered by studying the eﬀect of NO-ASA on
PPARδ. Our work is presented in the following section.6 PPAR Research
5. NO-NSAIDs AND PPARδ
Our limited understanding of the mechanism by which
NO-ASA exerts its colon chemopreventive eﬀect combined
with the possibility that PPARδ plays a role in colon
carcinogenesis prompted us to assess the expression of
PPARδ during intestinal carcinogenesis, and also whether
NO-ASA modulates it [7].
We studied Min mice and their congenic (wild-type)
mice, C57BL/6J+/+. Three groups of each type of mice were
treated for 21days with vehicle or m-NO-ASA or p-NO-
ASA, each at 100mg/kg/day. As expected from their relative
in vitro potency, after 21days m-NO-ASA suppressed the
number of intestinal tumors in Min mice (wt mice had no
tumors) by 38%, and p-NO-ASA by 59%.
Most of the PPARδ positive cells (staining being always
nuclear) were in the intestinal villi, with only few in the
crypts. PPARδ was minimally expressed among the three
groups of wild-typemice. In contrast, the expression of
PPARδ in Min mice, similar in tumors and histologically
normal mucosa, was more than ten-fold increased compared
to wild-type mice. The two NO-ASA positional isomers
inhibited the expression of PPARδ in both normal and
neoplastic cells of Min mice. m-NO-ASA suppressed PPARδ
expression in histologically normal mucosa by 23% and
in neoplastic tissue by 41%; p-NO-ASA suppressed PPARδ
expression in histologically normal mucosa by 27% and by
55% in neoplastic tissue. The reduction in the number of
tumors by each NO-ASA isomer and the respective suppres-
sion of PPARδ expression in neoplastic cells are strikingly
similar; the meta isomer reduced tumor incidence by 38%
and PPARδ expressionby 42%, whereas the corresponding
reductionfortheparaisomerwas59%and55%.Ofnote,the
expression of PPARα and PPARγ was sparse, and treatment
with NO-ASA had no appreciable eﬀect on either of them.
The changes in PPARδ expression induced by NO-ASA
seemed to have a signiﬁcant impact on the cell kinetics of the
intestinal mucosa, rendering such an eﬀect mechanistically
important. The induction of apoptosis by NO-ASA, more
prominent in neoplastic epithelial cells, followed closely the
pattern of PPARδ reduction. Thus, in the neoplastic tissues,
m-NO-ASA increased apoptosis by 22% and p-NO-ASA by
70%. The percentage of changes in PPARδ expression and
apoptosis is signiﬁcantly correlated (P<. 03), suggesting a
potential etiological association between the two events.
We have previously reported that NO-ASA induces two
types of cell death, classical apoptosis as well as atypical
cell death, which based on a variety of criteria appears to
be a variant of necrosis [4]. Documentation of atypical
cell death in vivo had been elusive. This study, however,
provided a glimpse into this phenomenon in vivo. As shown
in Figure 2,w ew e r ea b l et or e c o r dt h ee v o l u t i o no fn e c r o t i c
areas in NO-ASA-treated intestinal tumors. Initially, TUNEL
positive cells coalesce and, as the necrotic area develops,
they populate its margins (being extremely rare in the
surrounding tissue). As the necrotic area increases in size,
the TUNEL positive cells persist at the margins. We have
identiﬁed multiple TUNEL positive spots within the necrotic
areas, suggesting their cellular origin. We believe that these
TUNEL positive cells are necrotic cells [78]. The relationship
ofPPARδ andcelldeathinducedbyNO-ASAwasascertained
by studying successive sections of intestinal tumors from
both treated and untreated animals (Figure 2). Untreated
tumors show strong PPARδ expression and few apoptotic
cells. After treatment with meta or para NO-ASA, tumors
show decreased PPARδ expression and increased apoptosis.
If the apoptosis index of tumors from NO-ASA-treated mice
is plotted against the expression of PPARδ, the association
between the two is statistically signiﬁcant; Figure 2 makes
this correlation obvious. It should, however, be pointed out
that these data have two methodological limitations. First,
the speciﬁcity of the antibody is not considered by experts
in the ﬁeld ideal for immunohistochemistry, as nonspeciﬁc
binding is possible. Second, no corroborating methodology
w a se m p l o y e ds u c ha sd e t e rm i n a t i o no fP P A R δ protein levels
in these tissues by immunoblotting.
Other NSAIDs such as aspirin (of which NO-ASA is a
derivative) have been reported to have PPARδ as one of their
molecular targets. In epithelial ovarian cancer cells, aspirin
suppressed PPARδ function and cell growth by inhibiting
ERK1/2[50].Sulindacsulﬁdeandindomethacininhibitboth
14-3-3 proteins and PPARδ levels in HT29 cells, suggest-
ing that this could be the mechanism by which NSAIDs
induce apoptosis in colorectal cancer [79]. Furthermore, in
SW480 cells, sulindac sulfone signiﬁcantly decreased PPARδ
expression more potently than the sulﬁde metabolite [80].
A case-control study in a large population showed that
a polymorphism in the promoter of PPARδ modiﬁed the
protective eﬀect of NSAIDs on colorectal adenomas [81].
However,theoppositewasobservedbyanothergroup,which
found that regular NSAIDs use reduced the risk of colorectal
cancer,butnoneofthepolymorphicgenesstudied,including
PPARδ, modiﬁed their protective eﬀect [82].
Several reports present evidence that NSAIDs induce
apoptosis independently of PPARδ. For example, sulindac
signiﬁcantly inhibited chemically induced skin carcinogene-
s i si nb o t hwi l d - t yp ea n dP P A R δ-null mice [83]. In addition,
aspirin-induced apoptosis in Jurkat cells was not mediated
by PPARδ [84]. Aspirin at a concentration which induces
apoptosis did not aﬀect the DNA binding of PPARδ,w h e r e a s
neither addition of a speciﬁc PPARδ ligand nor transient
transfection of PPARδ expression vectors protected Jurkat
cells from aspirin-induced apoptosis. Finally, as the work
of Hollingshead et al. presented above suggested, COX-2
inhibition by the NSAID nimesulide and PPARδ activation
during colon carcinogenesis occurred through independent
mechanisms [62].
6. CONCLUSIONSAND FUTURE DIRECTIONS
The contrast in data that were reviewed here on the potential
role of PPARδ in cancer, with colon cancer being most
extensively evaluated, could not be starker. Excellent studies
from ﬁne laboratories led “conclusively” to diametrically
opposite results. As no grey zone seems to exist, the reader
is left in bewilderment.
Our data indicate that, compared to wild-type mice, the
nuclear receptor PPARδ is overexpressed in the intestinalGerardo G. Mackenzie et al. 7
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Figure 2: Eﬀect of NO-ASA on PPARδ and apoptosis in colon tissue of Min mice. Upper panel: the evolution of necrotic areas in intestinal
tumors treated with p-NO-ASA; sections are stained by the TUNEL method. (I) Coalescence of TUNEL positive cells (arrow), representing
theearlieststage;(II)abundantapoptoticcellsatthemarginsofthedevelopingareawithcontrasttotheirrarityinthesurroundingarea;(III)
and(IV)thenecroticareaisincreasinginsize,butTUNELpositivecellspersistatitsmargins;TUNELpositiveareaswithinthenecroticareas
(arrows) suggest their cellular origin. Lower panel: the relationship of PPARδ and apoptosis in NO-ASA treated intestinal tumors. Successive
sectionsofintestinaltumorswerestainedforPPARδ expressionandapoptosis.TheuntreatedtumorshowsstrongPPARδ expression(A)and
rare apoptotic cells (B). After treatment with meta or para NO-ASA, tumors show decreased PPARδ expression (C) and (E) and increased
apoptosis (D) and (F). Magniﬁcation is x400, adapted from Ouyang et al. [7].
mucosa of Min mice, and that two isomers of NO-ASA,
which suppress their intestinal neoplasia, inhibit to a com-
mensuratedegreetheexpressionofPPARδ aswell.Thiseﬀect
is accompanied by the induction of epithelial cell death,
which correlates well with the antineoplastic eﬀect of NO-
ASA.Asdiscussedearlier,theseﬁndingsare,however,limited
bythefactthatPPARδ wasdetectedusinganantibody whose
speciﬁcity may not be perfect and also by the lack of any
corroborating methodology (e.g., immunoblot detection of
PPARδ levels).
Onecould,nevertheless,considerthattheseﬁndingssup-
port the notion that PPARδ promotes colon carcinogenesis.
The key elements of support come from three ﬁndings. First,
PPARδ is overexpressed in the intestinal mucosa of the Min
mice but not in the wild-type control mice; being the same
in histologically normal and neoplastic mucosas further
suggests that it has a role in early events of carcinogenesis.
There is also speciﬁcity in the induction of PPARδ, as neither
PPARα nor PPARγ was induced. Second, PPARδ responds
to two NO-ASA molecules that are structurally identical
except for their positional isomerism, proportionally to their
antitumor eﬀect. And, third, changes in tumor response,
PPARδ, and cytokinetic parameters (apoptosis and necrosis)
are closely correlated and mechanistically congruent.
Clarifying the role of PPARδ in colon carcinogenesis and
the response to medications is of substantial interest. The
mechanistic signiﬁcance of this question is apparent. The
implications for the rational design of therapeutic and/or
preventive approaches are also clear. Finally, the fact that
PPARδ agonists may be used for other indications raises the8 PPAR Research
concern of unintended consequences of such modulation of
PPARδ, which may have a direct eﬀect on the patient’s risk of
colon and perhaps other cancers.
At this stage, the jury should be considered out on
the role of PPARδ in cancer. As with any evolving ﬁeld,
the mundane but accurate conclusion is that more work is
needed to clarify such an important question.
ABBREVIATIONS
COX: Cyclooxygenase
MAPK: Mitogen-activated protein kinase
NSAIDs: Nonsteroidal anti-inﬂammatory drugs
NO-ASA: NO-donating aspirin
NO-NSAIDs: Nitric oxide-donating nonsteroidal
anti-inﬂammatory drugs
PPAR: Peroxisome proliferator-activated
receptor
TPA: O-tetradecanoylphorbol-13-acetate.
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